Disease reactivation or rebound,after Fingolimod cessation

This stuy summarized here,experiences of 50 patients of relapsing MS,who received fingolimod as a second line DMT for treatment of their disease,because failure of the 1ST line drug in the treatment of disease,or the 1ST drug (beta interferon or GA) was not working effectively to reduce clinical relapse or MRI activity and disease progression.Result..A total of 4 patients who had discontinued Fingolimod were included in this study, the 1ST patient who was a known case of RRMS and refused Tysabri or Rituximab as a 2end line DMD, was put on Fingolimod,had a relapse about one month after fingolimod discontinuation and additional 3 cases of RRMS,who had received Figolimod as a 2end line DMT, had an exacerbation of disease after 3 - 4 weeks after Fingolimod cessation,all of these patients responded to(3-5 gr /iv/mtp) with complete recovery.Conclusion.The present study showed that about 8% of patients are at risk of having a relapse within 4 weeks to 6 weeks after Fingolimod discontinuation and the risk of severe relapse and rebound is lower than has been previously described.